Christopher Rovaldi - Feb 1, 2022 Form 3 Insider Report for Keros Therapeutics, Inc. (KROS)

Role
Chief Operating Officer
Signature
/s/ Esther Cho, Attorney-in-Fact
Stock symbol
KROS
Transactions as of
Feb 1, 2022
Transactions value $
$0
Form type
3
Date filed
2/3/2022, 03:37 PM
Next filing
Apr 5, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding KROS Employee Stock Option (right to buy) Feb 1, 2022 Common Stock 2.3K $0.48 Direct F1
holding KROS Employee Stock Option (right to buy) Feb 1, 2022 Common Stock 10.6K $16.00 Direct F2
holding KROS Employee Stock Option (right to buy) Feb 1, 2022 Common Stock 20K $64.15 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One-fourth (1/4th) of the shares subject to the option vested on September 19, 2020, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.
F2 One-fourth (1/4th) of the shares subject to the option vested on January 1, 2021, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.
F3 One-fourth (1/4th) of the shares subject to the option shall vest on February 10, 2022, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.